Baxalta
| Baxalta Incorporated | |
|---|---|
| legal form | Incorporated |
| ISIN | US07177M1036 |
| founding | 2015 |
| resolution | 2016 |
| Reason for dissolution | Merger with Shire plc |
| Seat |
Bannockburn , Illinois , United States
|
| management | Ludwig N. Hantson ( President and CEO ) |
| Number of employees | 16,000 (2015) |
| sales | 5.9 billion US dollars (2015 expected) |
| Branch | Pharmacy , medical technology |
| Website | www.baxalta.com |
Baxalta Inc. was an American pharmaceutical company for biotechnological drugs with headquarters in Bannockburn , Illinois . It was created on 1 July 2015 spin (spin-off) , the Biotechnology Division of Baxter International , the last of around 6 billion US dollars generated revenue. In early 2016, Irish pharmaceutical company Shire plc acquired Baxalta for around $ 32 billion. In June 2016, was the fusion of the two companies completed plc for Shire.
Baxalta recently had around 16,000 employees, 4,000 of them at the subsidiary Baxalta Austria, and was listed on the New York Stock Exchange (NYSE: BXLT).
Baxalta has been a global leader in drugs for the treatment of hemophilia and other bleeding disorders, immune deficiencies , intraoperative wound care, and the development of certain vaccines against rare diseases.
Web links
Individual evidence
- ↑ a b http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9Mjg3NTE4fENoaWxkSUQ9LTF8VHlwZT0z&t=1
- ↑ Shire buys Baxalta: Rare diseases, rarely high purchase price . In: Handelsblatt , January 11, 2016, accessed on November 13, 2017.
- ↑ Shire merges with Baxalta and becomes the market leader in rare and complex diseases . Shire plc press release on finanzen.net, June 3, 2016, accessed November 13, 2017.